Premium
CD14/16 monocyte profiling in juvenile myelomonocytic leukemia
Author(s) -
Gadgeel Manisha,
Bagla Shruti,
Buck Steven,
Shamoun Mark,
Ravindranath Yaddanapudi
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28555
Subject(s) - juvenile myelomonocytic leukemia , chronic myelomonocytic leukemia , medicine , monocyte , leukemia , cd14 , ptpn11 , cancer research , cd16 , immunology , myelodysplastic syndromes , flow cytometry , bone marrow , biology , genetics , kras , haematopoiesis , stem cell , colorectal cancer , cd3 , cancer , antigen , cd8
Monocyte subset analysis by flow cytometry has been shown to be a useful diagnostic tool in chronic myelomonocytic leukemia in adults. An increase in the classical monocyte fraction (CD14++/CD16−) greater than 94.0% of total monocytes is considered highly sensitive and specific in distinguishing chronic myelomonocytic leukemia from other myeloproliferative disorders. In a pilot study of juvenile myelomonocytic leukemia cases, we noted that CD14++/CD16− monocyte fraction was >95% in de novo juvenile myelomonocytic leukemia (JMML) with somatic PTPN11 mutations but normal in those with monosomy 7 or Noonan syndrome. Monocyte subgroup profiling by itself is not diagnostic of JMML but may distinguish molecular subgroups within JMML.